Pharmacoeconomic evaluation is an analytical tool used with increasing frequency to assist decision making in the financing and management of pharmaceutical products in the healthcare system or national health insurance programs of an individual country. Pharmacoeconomic (PE) guidelines can be used as a standard for preparation of studies to be included in application for reimbursement, a guide for designing and conducting a study, or a template for evaluating the economic study reports.
What does "Pharmacoeconomic Guidelines Around the World" provide?
"Pharmacoeconomic Guidelines Around the World" provides the following for each country listed:
- The 33 key features are: (1) type, (2) title and year of the document, (3) affiliation of authors, (4) main policy objective, (5) standard reporting format included, (6) disclosure of funding/ authors' interests, (7) target audience,
(8) perspective, (9) indication, (10) target population, (11) subgroup analysis, (12) choice of comparator, (13) time horizon, (14) assumptions required, (15) preferred analytical technique, (16) costs to be included, (17) source of
costs, (18) modeling, (19) systematic review of evidences, (20) preference for effectiveness over efficacy, (21) preferred outcome measure, (22) preferred method to derive utility, (23) equity issue stated, (24) discounting costs,
(25) discounting outcomes, (26) sensitivity analysis- parameters and range, (27) sensitivity analysis- methods, (28) presenting results, (29) incremental analysis, (30) total C/E, (31) portability of results (generalizability), (32)
financial impact analysis, (33) mandatory or recommended or voluntary
- Each country-specific table also includes a hyperlink to the full text of the guideline (as copyright permission allows) or publication reference, as well as a map of the country
Guidelines listed are dated based on the publication date of the document and categorized as follows:
- Published PE Recommendations: they are country-specific economic evaluation guidelines or recommendations published by experts in the field but are not “officially” recognized or required by the healthcare decision-making bodies/entities in this country/region for reimbursement.
- PE Guidelines: they are country-specific “official” guidelines or policies concerning economic evaluation that are recognized or required by the healthcare decision-making bodies/entities in this country/region for reimbursement.
- Submission Guidelines: they are country-specific “official” guidelines or policies concerning drug submission requirements with an economic evaluation part/section and are required by the healthcare decision-making bodies/entities in this country/region for reimbursement.
As a reference for the development of this information, please see: Health Care System Information Sharing. The reference citation is: Eldessouki
R, Smith MD, Health Care System Information Sharing: A Step Toward Better Health Globally. Value Health Regional Issues 2012; 1:118-129
Recently Updated Guidelines/Recommendations
-
Philippines
Updated: May 24, 2024 -
India
Updated: May 21, 2024 -
South Korea
Updated: May 21, 2024
| Published PE Recommendations | PE Guidelines | Submission Guidelines | |
|---|---|---|---|
| Africa | |||
| Asia Pacific (including Oceania) | |||
| Europe | |||
| Latin America | |||
| North America |
|
ISPOR routinely checks whether the guidelines listed here are current. If you know of any recent updates or any newly created guidelines not included here, please write us here.
If you would like your country’s pharmacoeconomics guidelines published on the ISPOR website or have comments/questions concerning this section of the ISPOR website, email your request here.